Current Environment: Production

Medical Services

Programs & Services

Languages

  • English

Certifications

  • American Board of Pediatrics (General)

Publications

  1. Racial/Ethnic Differences and Effects of Clinical/Socioeconomic Factors on Time from Diagnosis to Treatment in Pancreatic Cancer. J Gastrointest Cancer. 2025 Feb 15; 56(1):67. View Abstract

  2. Palliative Care and End-of-Life Care in Metastatic Pancreatic Cancer. J Palliat Med. 2025 Feb; 28(2):217-223. View Abstract

  3. Survival outcomes of adjuvant treatment in upstaged clinical T2N0 rectal cancer: are we underutilizing therapy? J Gastrointest Surg. 2025 Jan; 29(1):101869. View Abstract

  4. CT-Guided Adaptive Radiotherapy for the Treatment of Technically Challenging Oligometastatic Disease: A Case Report. Cureus. 2024 Oct; 16(10):e70765. View Abstract

  5. Adaptive Stereotactic Body Radiation Therapy in the Management of Oligometastatic Uterine Leiomyosarcoma: A Clinical Case Report. Cureus. 2024 Sep; 16(9):e68572. View Abstract

  6. Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery. Qual Life Res. 2024 Oct; 33(10):2833-2844. View Abstract

  7. Factors Associated With Racial and Ethnic Disparities in Locally Advanced Rectal Cancer Outcomes. JAMA Netw Open. 2024 02 05; 7(2):e240044. View Abstract

  8. NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer. J Natl Cancer Inst. 2023 12 06; 115(12):1457-1464. View Abstract

  9. Survival and Toxicity in Patients With Unresectable or Inoperable Biliary Tract Cancers With Ablative Radiation Therapy Versus Nonablative Chemoradiation. Adv Radiat Oncol. 2024 Apr; 9(4):101412. View Abstract

  10. Source, co-occurrence, and prognostic value of PTEN mutations or loss in colorectal cancer. NPJ Genom Med. 2023 Nov 24; 8(1):40. View Abstract

  11. Understanding the Challenges Faced by Esophageal and Gastroesophageal Junction Cancer Survivors. J Patient Exp. 2023; 10:23743735231179545. View Abstract

  12. Comparing Lifestyle Modifications and the Magnitude of Their Associated Benefit on Cancer Mortality. Nutrients. 2023 Apr 23; 15(9). View Abstract

  13. Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials: A Secondary Analysis of NRG Oncology Randomized Clinical Trials. JAMA Netw Open. 2023 04 03; 6(4):e238504. View Abstract

  14. The Role of Dose Escalation in Pancreatic Cancer: Go Big or Go Home? Int J Radiat Oncol Biol Phys. 2023 02 01; 115(2):395-397. View Abstract

  15. Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529. Am J Clin Oncol. 2022 12 01; 45(12):534-536. View Abstract

  16. Real-world Use of Radiation for Newly Diagnosed Brain Metastases in Patients With ALK-positive Lung Cancer Receiving First-line ALK Inhibitor. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):627-634. View Abstract

  17. Delineating the RAS Conformational Landscape. Cancer Res. 2022 07 05; 82(13):2485-2498. View Abstract

  18. The American Brachytherapy Society consensus statement for permanent implant brachytherapy using Yttrium-90 microsphere radioembolization for liver tumors. Brachytherapy. 2022 Sep-Oct; 21(5):569-591. View Abstract

  19. Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers. Nat Commun. 2022 03 25; 13(1):1618. View Abstract

  20. Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology. Cancer Treat Rev. 2022 Mar; 104:102337. View Abstract

  21. The association of age with acute toxicities in NRG oncology combined modality lower GI cancer trials. J Geriatr Oncol. 2022 04; 13(3):294-301. View Abstract

  22. Initial Clinical Experience With Novel Directional Low-Dose Rate Brachytherapy for Retroperitoneal Sarcoma. J Surg Res. 2021 12; 268:411-418. View Abstract

  23. A Case of Radiation Recall Myositis and Neuropathy in Locally Advanced Rectal Cancer. Adv Radiat Oncol. 2021 Nov-Dec; 6(6):100770. View Abstract

  24. Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma. Ann Surg Oncol. 2022 Jan; 29(1):354-363. View Abstract

  25. ASO Author Reflections: Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma. Ann Surg Oncol. 2022 01; 29(1):364-365. View Abstract

  26. MRI-Guided Focused Ultrasound of Osseous Metastases: Treatment Parameters Associated With Successful Pain Reduction. Invest Radiol. 2021 03 01; 56(3):141-146. View Abstract

  27. Pancreatic cancer in the era of COVID-19 pandemic: Which one is the lesser of two evils? World J Clin Oncol. 2021 Feb 24; 12(2):54-60. View Abstract

  28. Predicting positive peritoneal cytology in pancreatic cancer. J Cancer Res Clin Oncol. 2021 Jun; 147(6):1825-1832. View Abstract

  29. Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal Cancer. JCO Clin Cancer Inform. 2021 01; 5:125-133. View Abstract

  30. Impact of Clinical Markers of Nutritional Status and Feeding Jejunostomy Use on Outcomes in Esophageal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy. Nutrients. 2020 Oct 17; 12(10). View Abstract

  31. Practical Clinical Implementation of the Special Physics Consultation Process in the Re-irradiation Environment. Adv Radiat Oncol. 2021 Jan-Feb; 6(1):100594. View Abstract

  32. Pelvic Reirradiation Utilizing Pulsed Low-dose Rate Radiation Therapy. Am J Clin Oncol. 2020 10; 43(10):748-751. View Abstract

  33. Patterns of Failure and Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. Ann Surg Oncol. 2020 Dec; 27(13):4867-4869. View Abstract

  34. Toxicity and outcomes in older versus younger patients treated with trimodality therapy for locally advanced rectal cancer. J Geriatr Oncol. 2020 11; 11(8):1331-1334. View Abstract

  35. Predictors of Distant Recurrence Following Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. Am J Clin Oncol. 2020 04; 43(4):243-248. View Abstract

  36. Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704. Oncologist. 2020 03; 25(3):e477-e483. View Abstract

  37. Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nat Commun. 2019 08 19; 10(1):3722. View Abstract

  38. Treatment-related toxicity and outcomes in older versus younger patients with esophageal cancer treated with neoadjuvant chemoradiation. J Geriatr Oncol. 2020 05; 11(4):668-674. View Abstract

  39. Impact of PET/CT for Restaging Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation. J Surg Res. 2019 11; 243:242-248. View Abstract

  40. Dose Escalation in Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Meta-Analysis. Am J Clin Oncol. 2019 01; 42(1):46-55. View Abstract

  41. External beam radiation therapy (EBRT) for asymptomatic bone metastases in patients with solid tumors reduces the risk of skeletal-related events (SREs). Ann Palliat Med. 2019 Apr; 8(2):159-167. View Abstract

  42. Concurrent chemoradiation for resected gall bladder cancers and cholangiocarcinomas. J Gastrointest Oncol. 2018 Aug; 9(4):762-768. View Abstract

  43. Predictive Value of Leukocyte- and Platelet-Derived Ratios in Rectal Adenocarcinoma. J Surg Res. 2018 12; 232:275-282. View Abstract

  44. Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Adv Radiat Oncol. 2018 Apr-Jun; 3(2):154-162. View Abstract

  45. Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol. 2018 Feb 08; 4(2):e173580. View Abstract

  46. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol. 2018 Jan; 41(1):59-64. View Abstract

  47. Local Control and Toxicity of External Beam Reirradiation With a Pulsed Low-dose-rate Technique. Int J Radiat Oncol Biol Phys. 2018 03 15; 100(4):959-964. View Abstract

  48. Deviations From Standard Chemoradiation Among Early-Stage Anal Cancer Patients. Int J Radiat Oncol Biol Phys. 2018 03 15; 100(4):945-949. View Abstract

  49. Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. Adv Radiat Oncol. 2018 Jan-Mar; 3(1):34-41. View Abstract

  50. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol. 2017 Aug; 40(4):393-398. View Abstract

  51. Optimal Use of Combined Modality Therapy in the Treatment of Esophageal Cancer. Surg Oncol Clin N Am. 2017 07; 26(3):405-429. View Abstract

  52. Tissue TGF-ß expression following conventional radiotherapy and pulsed low-dose-rate radiation. Cell Cycle. 2017 Jun 18; 16(12):1171-1174. View Abstract

  53. Splenic irradiation for splenomegaly: A systematic review. Cancer Treat Rev. 2017 Feb; 53:47-52. View Abstract

  54. Disparities in the Local Management of Breast Cancer in the US according to Health Insurance Status. Breast J. 2017 Mar; 23(2):169-176. View Abstract

  55. Absence of Pathological Proof of Cancer Associated with Improved Outcomes in Early-Stage Lung Cancer. J Thorac Oncol. 2016 07; 11(7):1112-20. View Abstract

  56. In regard to Wu and Vapiwala et al. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):858-9. View Abstract

  57. Risk of radiation pneumonitis in patients receiving taxane-based trimodality therapy for locally advanced esophageal cancer. Pract Radiat Oncol. 2016 Nov - Dec; 6(6):388-394. View Abstract

  58. Dosimetric and delivery efficiency investigation for treating hepatic lesions with a MLC-equipped robotic radiosurgery-radiotherapy combined system. Med Phys. 2016 Feb; 43(2):727-33. View Abstract

  59. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 2016 May 01; 122(9):1349-69. View Abstract

  60. Young Age Increases Risk of Lymph Node Positivity in Early-Stage Rectal Cancer. J Natl Cancer Inst. 2016 Jan; 108(1). View Abstract

  61. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget. 2015 Dec 22; 6(41):43594-604. View Abstract

  62. Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer. Acta Oncol. 2016; 55(3):303-8. View Abstract

  63. Dosimetric predictors of hematologic toxicity in patients undergoing concurrent gemcitabine-based chemoradiation for localized pancreatic cancer. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):e107-e115. View Abstract

  64. What Are Medical Students in the United States Learning About Radiation Oncology? Results of a Multi-Institutional Survey. Int J Radiat Oncol Biol Phys. 2016 Feb 01; 94(2):235-42. View Abstract

  65. Association of treatment factors with surgical outcomes in tri-modality therapy for esophageal cancer. J Surg Oncol. 2015 Nov; 112(6):629-33. View Abstract

  66. Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Pract Radiat Oncol. 2015 Sep-Oct; 5(5):e457-e463. View Abstract

  67. Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. Ann Thorac Surg. 2015 Jan; 99(1):270-6. View Abstract

  68. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiother Oncol. 2014 Oct; 113(1):35-40. View Abstract

  69. Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results. J Natl Cancer Inst. 2014 Apr 23; 106(5). View Abstract

  70. HIV positivity but not HPV/p16 status is associated with higher recurrence rate in anal cancer. J Gastrointest Cancer. 2013 Dec; 44(4):450-5. View Abstract

  71. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter? Ann Surg Oncol. 2014 Feb; 21(2):662-9. View Abstract

  72. Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinoma. Pract Radiat Oncol. 2013 Oct-Dec; 3(4):e149-55. View Abstract

  73. Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. HPB (Oxford). 2014 Jan; 16(1):34-9. View Abstract

  74. When less is more, when less is less: local excision in early rectal cancer. Gastrointest Cancer Res. 2009 May; 3(3):123-4. View Abstract

  75. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):1128-33. View Abstract

  76. Radiation therapy toxicity to the skin. Dermatol Clin. 2008 Jan; 26(1):161-72, ix. View Abstract

  77. The effect of radiation therapy on normal tissue function. Hematol Oncol Clin North Am. 2006 Feb; 20(1):141-63. View Abstract
BESbswy